Radiogenomics predicting tumor responses to radiotherapy in lung cancer

Seminars in Radiation Oncology

Volumn 20, Issue 3, 2010, Pages 149-155

  Das, Amit K ^a   Bell, Marcus H ^a   Nirodi, Chaitanya S ^b   Story, Michael D ^b   Minna, John D ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BEVACIZUMAB; BIOLOGICAL MARKER; LONAFARNIB; TIPIFARNIB;

CANCER GENETICS; CANCER RADIOTHERAPY; CLINICAL TRIAL; DRUG MECHANISM; GENETIC ANALYSIS; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

CARCINOMA, NON-SMALL-CELL LUNG; GENOMICS; HUMANS; LUNG NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77954853984     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semradonc.2010.01.002     Document Type: Review

References (34)

1. Jemal A., Siegel R., Ward E. Cancer statistics, 2006. CA Cancer J Clin 2006, 56:106-130.
2. Parkin D.M., Bray F., Ferlay J. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
3. Shedden K., Taylor J.M., Enkemann S.A. Gene expression-based survival prediction in lung adenocarcinoma: A multi-site, blinded validation study. Nat Med 2008, 14:822-827.
4. Sun S., Schiller J.H., Spinola M. New molecularly targeted therapies for lung cancer. J Clin Invest 2007, 117:2740-2750.
5. Carmichael J., Degraff W.G., Gamson J. Radiation sensitivity of human lung cancer cell lines. Eur J Cancer Clin Oncol 1989, 25:527-534.
6. Sato M., Shames D.S., Gazdar A.F. A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol 2007, 2:327-343.
7. Sabbatini P., Korenchuk S., Rowand J.L. GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. Mol Cancer Ther 2009, 8:2811-2820.
8. McDermott U., Iafrate A.J., Gray N.S. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 2008, 68:3389-3395.
9. Pao W., Kris M.G., Iafrate A.J. Integration of molecular profiling into the lung cancer clinic. Clin Cancer Res 2009, 15:5317-5322.
10. Minna J.D., Girard L. Xie Y: Tumor mRNA expression profiles predict responses to chemotherapy. J Clin Oncol 2007, 25:4329-4336.
11. Hwang I.G., Ahn M.J., Park B.B. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy. Cancer 2008, 113:1379-1386.
12. Fujii T., Toyooka S., Ichimura K. ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer. Lung Cancer 2008, 59:377-384.
13. Lee H.W., Han J.H., Kim J.H. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer. Lung Cancer 2008, 59:95-104.
14. Das A.K., Sato M., Story M.D. Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation. Cancer Res 2006, 66:9601-9608.
15. Raben D., Helfrich B., Bunn P.A. Targeted therapies for non-small-cell lung cancer: Biology, rationale, and preclinical results from a radiation oncology perspective. Int J Radiat Oncol Biol Phys 2004, 59(2 Suppl):27-38.
16. Das A.K., Chen B.P., Story M.D. Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lung carcinoma. Cancer Res 2007, 67:5267-5274.
17. Chinnaiyan P., Huang S., Vallabhaneni G. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 2005, 65:3328-3335.
18. Shibuya K., Komaki R., Shintani T. Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2007, 69:1534-1543.
19. Reck M., Crino L. Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer. Lung Cancer 2009, 63:1-9.
20. Brognard J., Clark A.S., Ni Y. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001, 61:3986-3997.
21. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003, 3:11-22.
22. Isobe T., Herbst R.S., Onn A. Current management of advanced non-small cell lung cancer: Targeted therapy. Semin Oncol 2005, 32:315-328.
23. Sung H.J., Cho J.Y. Biomarkers for the lung cancer diagnosis and their advances in proteomics. BMB Rep 2008, 41:615-625.
24. Singhal S., Miller D., Ramalingam S. Gene expression profiling of non-small cell lung cancer. Lung Cancer 2008, 60:313-324.
25. Fichtner I., Rolff J., Soong R. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res 2008, 14:6456-6468.
26. Torres-Roca J.F., Eschrich S., Zhao H. Prediction of radiation sensitivity using a gene expression classifier. Cancer Res 2005, 65:7169-7176.
27. Amundson S.A., Do K.T., Vinikoor L.C. Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute anticancer drug screen. Cancer Res 2008, 68:415-424.
28. Ross D.T., Scherf U., Eisen M.B. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000, 24:227-235.
29. Shankavaram U.T., Reinhold W.C., Nishizuka S. Transcript and protein expression profiles of the NCI-60 cancer cell panel: An integromic microarray study. Mol Cancer Ther 2007, 6:820-832.
30. Eschrich S., Zhang H., Zhao H. Systems biology modeling of the radiation sensitivity network: A biomarker discovery platform. Int J Radiat Oncol Biol Phys 2009, 75:497-505.
31. Ransohoff D.F. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 2004, 4:309-314.
32. Bayman N.A., Sheikh H., Kularatne B. Radiotherapy for small-cell lung cancer-where are we heading?. Lung Cancer 2009, 63:307-314.
33. Carney D.N., Mitchell J.B., Kinsella T.J. In vitro radiation and chemotherapy sensitivity of established cell lines of human small cell lung cancer and its large cell morphological variants. Cancer Res 1983, 43:2806-2811.
34. Milas L., Hittelman W.N. Cancer stem cells and tumor response to therapy: Current problems and future prospects. Semin Radiat Oncol 2009, 19:96-105.